14E-tricosenoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 14E-tricosenoic acid
• 英文别名: (E)-tricos-14-enoic acid
• 化学式: C₂₃H₄₄O₂
• 分子量: 352.6
• InChiKey: BRCMIDDAOIVEAZ-MDZDMXLPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.2
• 重原子数：
  25
• 可旋转键数：
  20
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  甲醇 、 14E-tricosenoic acid 生成 methyl (E)-tricos-14-enoate
  参考文献：
  名称：

  REZANKA, TOMAS;MARES, PREMYSL, J. CHROMATOGR., 409,(1987) 390-395

  摘要：

  DOI：

文献信息

• HOLLOW FIBROUS ORGANIC NANOTUBE AND PRODUCTION METHOD THEREOF
  申请人：Asakawa Masumi

  公开号：US20090202641A1

  公开（公告）日：2009-08-13

  Disclosed is a method of synthesizing a water-free nanotube capable of efficiently encapsulating a functional substance therein, in large quantities. The method comprises: dissolving, in an organic solvent heated up to a temperature equal to or less than a boiling point thereof, an N-glycoside type glycolipid represented by the following general formula (1): G-NHCO—R 1 (wherein G represents a sugar residue from which a hemiacetal hydroxyl group bonded to an anomeric carbon atom of the sugar is excluded; and R 1 represents an unsaturated hydrocarbon group having 10 to 39 carbon atoms), or a peptide-lipid conjugate represented by one of the following general formulas (2) and (3): R 2 CO(NH—CHR 3 —CO) m OH and H(NH—CHR 3 —CO) m NHR 2 (wherein: R 2 represents a hydrocarbon group having 6 to 24 carbon atoms; R 3 represents an amino-acid side chain; and m represents an integer of 1 to 10); (i) slowly cooling the obtained solution, and maintaining the cooled solution undisturbed at room temperature, or (ii) concentrating the obtained solution, and maintaining the concentrated solution disturbed at room temperature, or (iii) adding to the obtained solution a poor solvent for the N-glycoside type glycolipid or the peptide-lipid conjugate, and maintaining the mixed solution undisturbed at room temperature; collecting from the resulting solution a hollow fibrous organic nanotube formed through self-assembling in the stationary solution, and drying the collected hollow fibrous organic nanotube, in air at room temperature or by heating under reduced-pressure, to obtain a hollow fibrous organic nanotube.

  本发明公开了一种合成无水纳米管的方法，该方法能够大量高效地封装功能物质。该方法包括：将下列通式（1）所表示的N-糖苷型糖脂或下列通式（2）和（3）所表示的肽-脂共轭物溶解于加热至沸点以下温度的有机溶剂中，其中，通式（1）中，G代表糖的缩合物，缩合物的半乙醇羟基与糖的缩合物的一个非环氧碳原子上的氢原子形成的羟基不包括在内；R1代表具有10至39个碳原子的不饱和烃基；通式（2）和（3）中，R2代表具有6至24个碳原子的碳氢基；R3代表氨基酸侧链；m代表1至10的整数。然后，（i）缓慢冷却所得溶液，并在室温下保持冷却的溶液不受干扰，或（ii）浓缩所得溶液，并在室温下保持浓缩的溶液受干扰，或（iii）向所得溶液中加入N-糖苷型糖脂或肽-脂共轭物的劣溶剂，并在室温下保持混合溶液不受干扰；从得到的溶液中收集在静止溶液中自组装形成的空心纤维有机纳米管，并通过在室温下空气干燥或在减压下加热干燥来获得空心纤维有机纳米管。
• MEDICINAL COMPOSITION FOR ORAL ADMINISTRATION
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP1188440A1

  公开（公告）日：2002-03-20

  The present invention is to provide a stabilized pharmaceutical composition for oral use containing 1-ethyl methylester 4-[[3-[p-(carboxyamidino)phenyl]-2-oxo-5-oxazolidinyl]meth yl]-1-piperazineacetate or a pharmaceutically acceptable salt thereof having an antagonistic action to GPIIb/IIIa receptor and an oily base. The present invention is to further provide a method for the manufacture of a stabilized pharmaceutical composition for oral use by compounding 1-ethyl methylester 4-[[3-[p-(carboxyamidino)phenyl]-2-oxo-5-oxazolidinyl]meth yl]-1-piperazineacetate or a pharmaceutically acceptable salt thereof with an oily base. The present invention is to furthermore provide a method for the stabilization of a pharmaceutical composition by compounding 1-ethyl methylester 4-[[3-[p-(carboxyamidino)phenyl]-2-oxo-5-oxazolidinyl]-met hyl]-1-piperazineacetate or a pharmaceutically acceptable salt thereof with an oily base.

  本发明旨在提供一种口服用稳定药物组合物，该组合物含有对GPIIb/IIIa受体具有拮抗作用的1-乙基甲酯4-[[3-[对(羧基氨基)苯基]-2-氧代-5-恶唑烷基]甲基]-1-哌嗪乙酸酯或其药学上可接受的盐以及油性碱。本发明进一步提供一种通过将 1-乙基甲酯 4-[[3-[p-(羧基脒基)苯基]-2-氧代-5-恶唑烷基]甲基]-1-哌嗪乙酸酯或其药学上可接受的盐与油性碱复配来制造口服用稳定药物组合物的方法。本发明进一步提供了一种稳定药物组合物的方法，即用油性碱复配 1-乙基甲酯 4-[[3-[对(羧基氨基)苯基]-2-氧代-5-恶唑烷基]甲基]-1-哌嗪乙酸酯或其药学上可接受的盐。
• N-GLYCOSIDE TYPE GLYCOLIPIDS AND HOLLOW FIBER TYPE ORGANIC NANOTUBES MADE OF THE SAME
  申请人：Japan Science and Technology Agency

  公开号：EP1609796A1

  公开（公告）日：2005-12-28

  Presents novel hollow fiber shaped organic nanotubes that can be easily produced in a short time span and also have a broad range of utility. An N-glycoside type glycolipid represented by the general formula (1) shown below.         G-NHCO-R     (1) (In the formula, G represents a saccharide radical other than a hemiacetal hydroxyl group bonded to the anomer carbon atom of the saccharide, and R represents an unsaturated hydrocarbon group containing ten to 39 carbon atoms.) This molecule self-aggregates and forms hollow fiber shaped organic nanotubes in water when this N-glycoside type glycolipid is dissolved, allowed to cool gradually and allowed to stand undisturbed at room temperature. The average external diameter of the nanotubes is from 70 nm to 500 nm and the average internal diameter (average diameter of the cavity) is from 40 nm to 300 nm.

  提出了新颖的中空纤维状有机纳米管，可在短时间内轻松生产，而且具有广泛的实用性。一种 N-糖苷型糖脂，其通式（1）如下所示。 G-NHCO-R (1) (式中，G 代表与糖的同分异构体碳原子结合的半缩醛羟基以外的糖基，R 代表含有 10 至 39 个碳原子的不饱和烃基）。当溶解这种 N-糖苷型糖脂，使其逐渐冷却并在室温下静置不受干扰时，这种分子会在水中自聚并形成中空纤维状有机纳米管。纳米管的平均外径为 70 纳米至 500 纳米，平均内径（空腔的平均直径）为 40 纳米至 300 纳米。
• HOLLOW-FIBER-LIKE ORGANIC NANOTUBE AND PROCESS FOR PRODUCTION THEREOF
  申请人：National Institute of Advanced Industrial Science and Technology

  公开号：EP2033934A1

  公开（公告）日：2009-03-11

  Disclosed is a method of synthesizing a water-free nanotube capable of efficiently encapsulating a functional substance therein, in large quantities. The method comprises: dissolving, in an organic solvent heated up to a temperature equal to or less than a boiling point thereof, an N-glycoside type glycolipid represented by the following general formula (1): G-NHCO-R1 (wherein G represents a sugar residue from which a hemiacetal hydroxyl group bonded to an anomeric carbon atom of the sugar is excluded; and R1 represents an unsaturated hydrocarbon group having 10 to 39 carbon atoms), or a peptide-lipid conjugate represented by one of the following general formulas (2) and (3): R2CO (NH-CHR3-CO)m OH and H (NH-CHR3-CO)m NHR2 (wherein: R2 represents a hydrocarbon group having 6 to 24 carbon atoms; R3 represents an amino-acid side chain; and m represents an integer of 1 to 10); (i) slowly cooling the obtained solution, and maintaining the cooled solution undisturbed at room temperature, or (ii) concentrating the obtained solution, and maintaining the concentrated solution disturbed at room temperature, or (iii) adding to the obtained solution a poor solvent for the N-glycoside type glycolipid or the peptide-lipid conjugate, and maintaining the mixed solution undisturbed at room temperature; collecting from the resulting solution a hollow fibrous organic nanotube formed through self-assembling in the stationary solution, and drying the collected hollow fibrous organic nanotube, in air at room temperature or by heating under reduced-pressure, to obtain a hollow fibrous organic nanotube.

  本发明公开了一种合成无水纳米管的方法，该纳米管能够大量有效地封装功能物质。该方法包括：在加热至等于或低于其沸点温度的有机溶剂中溶解由以下通式（1）表示的 N-糖苷型糖脂：G-NHCO-R1（其中 G 代表糖残基，其中与糖的异构碳原子结合的半缩醛羟基被排除；R1 代表具有 10 至 39 个碳原子的不饱和烃基），或由下列通式（2）和（3）之一代表的肽脂共轭物：R2CO（NH-CHR3-CO）m OH 和 H（NH-CHR3-CO）m NHR2（其中：R2 代表具有 6 至 24 个碳原子的烃基；R3 代表氨基酸侧链；m 代表 1 至 10 的整数）；(i) 缓慢冷却所得溶液，并将冷却后的溶液保持在室温下不受干扰，或 (ii) 浓缩所得溶液，并将浓缩后的溶液保持在室温下不受干扰，或 (iii) 向所得溶液中加入 N-糖苷型糖脂或肽脂共轭物的劣溶剂，并将混合溶液保持在室温下不受干扰；从所得溶液中收集在固定溶液中自组装形成的中空纤维状有机纳米管，并在室温空气中或通过减压加热干燥所收集的中空纤维状有机纳米管，以获得中空纤维状有机纳米管。
• Assays for screening activity of modulators of members of the hydroxy steroid (17-beta) dehydrogenase (HSD17B) family
  申请人：Regeneron Pharmaceuticals, Inc.

  公开号：US11479802B2

  公开（公告）日：2022-10-25

  Screening methods as well as kits for identifying modulators of hydroxysteroid (17-beta) dehydrogenase (HSD17B) family member proteins, such as HSD17B13, are provided. The methods comprise screening molecules for their capacity to modulate the HSD17B family member protein, including inhibiting the HSD17B family member protein, as measured by substrate depletion, product concentration from the HSD17B family member protein substrate conversion or NADH concentration, levels of labeled substrate, luciferin light emission, or combinations thereof. Inhibitors of HSD17B family member proteins identified through the screening methods may be used to treat liver diseases, disorders, or conditions in which the HSD17B family member protein plays a role.

  本发明提供了用于鉴定羟基类固醇（17-beta）脱氢酶（HSD17B）家族成员蛋白（如 HSD17B13）调节剂的筛选方法和试剂盒。这些方法包括筛选分子，以确定其调节 HSD17B 家族成员蛋白的能力，包括抑制 HSD17B 家族成员蛋白的能力，通过底物耗竭、HSD17B 家族成员蛋白底物转化产物浓度或 NADH 浓度、标记底物水平、荧光素发光或其组合来测量。通过筛选方法鉴定的 HSD17B 家族成员蛋白的抑制剂可用于治疗 HSD17B 家族成员蛋白起作用的肝脏疾病、失调或病症。